论文部分内容阅读
自1975年米尔斯坦(Cesar Milstein)和科勒(Georges Kohler)首次建立单克隆抗体(Monoclonal Antibody)技术以来,受到医学和生物学家们的极大重视和世界厂商企业界的深切关注。这项技术不仅是研究细胞生物学,免疫学等学科的一种有力工具,而且还可提供诊断病毒、细菌、寄生虫、特别是癌细胞快速、准确的方法。杂交细胞瘤(Hybridomas)所产生的单克隆抗体还将为肿瘤治疗提供一条崭新的途径。因此,不少评论认为,单克隆技术的发明可导致免疫学以及与免疫学有关的领域,特别是肿瘤学研究的革命性发展。关于单克隆抗体制备的原理及一般程序,读者可参阅有关书籍和文献。本文只拟将肿瘤单克隆抗体研究进展作一简要的综述。
Since Cesar Milstein and Georges Kohler first established the monoclonal antibody (Monoclonal Antibody) technology in 1975, they have received great attention from medical and biologists and the deep concern of the world’s manufacturers. This technology is not only a powerful tool for the study of cell biology, immunology and other disciplines, but also provides a rapid and accurate method for the diagnosis of viruses, bacteria, parasites, and cancer cells in particular. Monoclonal antibodies produced by hybridoma (Hybridomas) will also provide a new approach to cancer treatment. Therefore, many commentators believe that the invention of monoclonal technology can lead to the development of immunology as well as the fields related to immunology, especially the research of oncology. For the principles and general procedures for the preparation of monoclonal antibodies, readers can refer to books and literature. This article only intends to make a brief review of the progress of tumor monoclonal antibodies.